N/A
Completed N=1,025
A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) Envelope
Source: ClinicalTrials.gov NCT02530970 ↗Enrolled (actual)
1,025
Serious AEs
3.9%
Results posted
Mar 2020
Primary outcomePrimary: Proportion of Subjects With ECM Related Adverse Events — 14; 2 Participants
Summary
The objective of the SECURE Study is to actively gather additional information on the use of the CorMatrix® CanGaroo ECM® Envelope in a post market observational study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Subjects With ECM Related Adverse Events |
14; 2 | — |
| PRIMARY Number of Participants With Major Pocket Infections |
12 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects who have received CorMatrix® CanGaroo ECM® Envelope for an implantable electronic device placement.
Exclusion Criteria
-
Data sourced from ClinicalTrials.gov (NCT02530970). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.